General guidance on exploratory and confirmatory subgroup analysis in late-stage clinical trials

被引:32
|
作者
Dmitrienko, Alex [1 ]
Muysers, Christoph [2 ]
Fritsch, Arno [3 ]
Lipkovich, Ilya
机构
[1] Quintiles, Ctr Stat Drug Dev, 6700 W 115th St, Overland Pk, KS 66209 USA
[2] Bayer HealthCare, Clin Stat, Berlin, Germany
[3] Bayer HealthCare, Clin Stat, Wuppertal, Germany
关键词
Biomarker evaluation; enrichment designs; regulatory guidance; subgroup analysis; subgroup identification; FRACTIONAL POLYNOMIALS; REGULATORY ISSUES; ADAPTIVE DESIGNS; SELECTION; IDENTIFICATION; CONSISTENCY; BIOMARKERS; FRAMEWORK;
D O I
10.1080/10543406.2015.1092033
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This article focuses on a broad class of statistical and clinical considerations related to the assessment of treatment effects across patient subgroups in late-stage clinical trials. This article begins with a comprehensive review of clinical trial literature and regulatory guidelines to help define scientifically sound approaches to evaluating subgroup effects in clinical trials. All commonly used types of subgroup analysis are considered in the article, including different variations of prospectively defined and post-hoc subgroup investigations. In the context of confirmatory subgroup analysis, key design and analysis options are presented, which includes conventional and innovative trial designs that support multi-population tailoring approaches. A detailed summary of exploratory subgroup analysis (with the purpose of either consistency assessment or subgroup identification) is also provided. The article promotes a more disciplined approach to post-hoc subgroup identification and formulates key principles that support reliable evaluation of subgroup effects in this setting.
引用
收藏
页码:71 / 98
页数:28
相关论文
共 50 条
  • [1] A review of therapeutic failures in late-stage clinical trials
    Jain, Ritu
    Subramanian, Janakiraman
    Rathore, Anurag S.
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (03) : 389 - 399
  • [2] Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials
    Alosh, Mohamed
    Huque, Mohammad F.
    Bretz, Frank
    D'Agostino, Ralph B., Sr.
    STATISTICS IN MEDICINE, 2017, 36 (08) : 1334 - 1360
  • [3] Exploratory subgroup analysis in clinical trials by model selection
    Rosenkranz, Gerd K.
    BIOMETRICAL JOURNAL, 2016, 58 (05) : 1217 - 1228
  • [4] Comments on "Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials"
    Zhang, Chuanwu
    Mayo, Matthew S.
    Gajewski, Byron J.
    STATISTICS IN MEDICINE, 2018, 37 (19) : 2900 - 2901
  • [5] DRUGMAKERS HURT BY LATE-STAGE TRIALS
    不详
    CHEMICAL & ENGINEERING NEWS, 2009, 87 (09) : 23 - 23
  • [6] A COMPARISON OF ANALYSIS METHODS FOR LATE-STAGE VARIETY EVALUATION TRIALS
    Welham, Sue J.
    Gogel, Beverley J.
    Smith, Alison B.
    Thompson, Robin
    Cullis, Brian R.
    AUSTRALIAN & NEW ZEALAND JOURNAL OF STATISTICS, 2010, 52 (02) : 125 - 149
  • [7] Carbon footprint of industry-sponsored late-stage clinical trials
    Mackillop, Neil
    Shah, Jayesh
    Collins, Michael
    Costelloe, Thomas
    Ohman, Daniel
    BMJ OPEN, 2023, 13 (08):
  • [8] Quantifying burden to improve patient experience in late-stage clinical trials
    Nowojewski, Andrzej
    Riesbeck, Ingrid
    Scetinina, Tatiana
    Teufel, Michele
    Esparza-Franco, Alejandro
    Schneider, Ian
    Dearden, Richard
    QUALITY OF LIFE RESEARCH, 2022, 31 : S45 - S45
  • [9] A new way to address missing data in late-stage clinical trials
    Ganju, Jitendra
    Yu, Ron Xiaolong
    CONTEMPORARY CLINICAL TRIALS, 2025, 148
  • [10] ADAPTIVE DESIGNS FOR CONFIRMATORY CLINICAL TRIALS WITH SUBGROUP SELECTION
    Stallard, Nigel
    Hamborg, Thomas
    Parsons, Nicholas
    Friede, Tim
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (01) : 168 - 187